The global Oncology-based In-vivo CRO Market was valued at around USD 1 Billion in 2021. With a projected CAGR of 10.9% for the next ten years, the market is likely to reach a valuation of nearly USD 2.9 by the end of 2033. The absolute dollar opportunity in the Oncology-based In-vivo CRO Market is anticipated to be at USD 1.8 Billion by 2033.
| Attributes | Details |
|---|---|
| Oncology-based In-vivo CRO Market Size (2021) | USD 1 Billion |
| Oncology-based In-vivo CRO Market Size (2023) | USD 1.1 Billion |
| Projected Market Value (2033) | USD 2.9 Billion |
| Global Market Growth Rate (2023 to 2033) | 10.9% CAGR |
| Share of Top 5 Countries | 56% |
| Key Companies Profiled | The Jackson Laboratory; EVOTEC; WuXi AppTec; Toxicon Inc.; Crown Bioscience; Taconic Biosciences; Eurofins Scientific; ICON Plc; Charles River Laboratory; Covance; Others |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Future Market Insights reveals that the Oncology-based in-vivo CRO market increased at a CAGR of 8.9% from 2018 to 2022 and is expected to achieve a growth rate of 10.9% from 2023 to 2033.
Oncology-based in-vivo CRO is expected to grow in the forecasted years due to a rise in the incidence of Oncology-based cases and the need to develop new drugs for the treatment of cancer patients. According to the World Health Organization, the global cancer burden increased to 19.3 million new cases and caused an anticipated 10 million deaths in 2020. This is driving the companies to outsource basic research activities and increase efficiency by focusing on key areas of development.
An increasing number of drugs being developed, new therapeutic modalities, advanced clinical practices, and emerging technologies have been driving the demand for Oncology-based in-vivo CRO. With the rising number of pharmaceutical companies, research and development activities are being outsourced to CRO services due to lower costs and focus on aspects that are more vital. CROs have gained the momentum to offer pharmaceutical organizations their research and development services and eliminate the hurdles that the companies face.
Companies generally outsource activities ranging from basic research to efficacy tests in animal models as well as late-stage clinical trials. Moreover, oncology is one of the most studied and researched domains due to the prevalence of cancer patients worldwide. With a number of oncology drugs being approved in recent years, necessitating new treatment options for patients, oncology still remains a challenging area for research and development. This is expected to propel the growth of Oncology-based in-vivo CRO.
Based on the research conducted by the Tufts Center for the study of Drug Development (CSDD), more than 75% of the top management of pharmaceutical companies agree that CROs are more time-efficient than internal teams, thereby expanding the scope of outsourcing. Besides, owing to specialization in the respective domain due to years of experience in the business, CROs are able to perform the task at an exceptionally greater speed.
Principal Consultant
Drug development for cancer is a research-intensive study. The development of the oncology-based in-vivo CRO industry is being constrained by a lack of infrastructure and financial support for research operations, particularly in low- and middle-income countries. Organizations engaged in oncology practices do not have enough resources to conduct research studies for the patients and are dependent upon the trials conducted by high-income countries, to provide focused and quality patient care. Moreover, strict regulatory approvals are another key obstacle fuelling the growth of Oncology-based in-vivo CRO.
The market in North America is likely to witness growth due to increasing research and development activities and demand to lower total trial expenditure. The availability of sizable investments in this area is expected to have an impact on the research efforts in the forecast period. Key pharmaceutical and life science firms that play a key role in the development of new drugs are also present in the region. The global oncology-based in-vivo CRO market in the region is anticipated to boost market expansion due to well-planned funding and advantageous regulatory policies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oncology-based In-vivo CRO Market in the USA. is valued at USD 1.2 Billion by 2033. Revenue through Oncology-based in-vivo CRO in the USA grew at 8.5% from 2018 to 2022 and is projected to achieve a growth rate of 11% over the forecast period.
This can be attributed due to the presence of several CROs present in the USA They are continuously getting funds and grants from government organizations to progress in the development of Oncology-based drug development. For instance, The Maine Cancer Genomics Initiative by Jackson laboratory is generating awareness and providing access to advanced genomic treatments, by characterizing the genetic profile of each patient’s cancer, thereby expanding the scope of educational programs in cancer genomics. The absolute dollar opportunity growth in Oncology-based in-vivo CROs in the USA is USD 827.5 Billion between 2023 and 2033.
Asia-Pacific has seen an emergence of Oncology-based research facilities due to increased research and developments in the region. For instance, in October 2020, Crown Bioscience expanded its Asia Pacific capacity by opening a new oncology-focused research facility in Zhongshan, China. The new research facility will offer 2,000 m2 to manage the in-vivo oncology platform.
Its currently existing facility is located in Beijing, Taicang and Suzhou, and Taiwan. Oncology-based in-vivo CRO facility in China is valued at USD 145.1 Million by 2033. The market accounted for a CAGR of 12.7% in China from 2018 to 2022. With the ongoing development of Oncology-based in-vivo CRO in China, it is no doubt that the absolute dollar opportunity growth will reach USD 95.8 Million by 2033.
The market in the UK is projected to reach a valuation of USD 194 Million by 2033. Growing at a CAGR of 11.8% from 2023 to 2033, the market is expected to gross an absolute dollar opportunity of 130 Million.
Solid tumors accounted for the top segment in oncology based in-vivo CRO. Revenue through solid tumors in the market grew at a CAGR of 8.6% during the period of 2018 to 2022. The projected CAGR of solid tumors in the Oncology-based In-vivo CRO Market is expected to be 11.2% over the forecast period. Around 90% of adult human cancers are represented by solid tumors.
The existence of over 800 novel compounds in the pipelines of key pharmaceutical firms, the accessibility of grants from organizations like the NIH and NCI, and the current therapeutic treatment gap for solid tumors are the elements driving increased research in the field of solid tumors.
Companies involved in the Oncology-based In-vivo CRO Market are largely aiming at setting up clinical facilities, winning orders, and aiming at developing drugs for the treatment of cancer. The key companies operating in the Oncology-based In-vivo CRO Market include The Jackson Laboratory, EVOTEC, WuXi AppTec, Toxicon Inc., Crown Bioscience, Taconic Biosciences, Eurofins Scientific, ICON Plc, Charles River Laboratory, and Covance.
Some of the recent developments by key providers of Oncology-based in-vivo CRO are as follows:
Similarly, recent developments related to companies involved in the Oncology-based in-vivo CRO market have been tracked by the team at Future Market Insights, which is available in the full report.
The market is valued at USD 1 Billion in 2023.
The market’s CAGR from 2023 to 2033 will be 10.9%.
From 2018 to 2022, the market registered an 8.9% CAGR.
China will generate USD 145.1 million revenue by 2033.
Solid tumors will be the key segment.
1. Executive Summary | Oncology-Based In-vivo CRO Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 5.1. Blood Cancer 5.1.1. Syngeneic Model 5.1.2. Patient-Derived Xenograft (PDX) 5.1.3. Xenograft 5.2. Solid Tumours 5.2.1. Syngeneic Model 5.2.2. Patient-Derived Xenograft (PDX) 5.2.3. Xenograft 5.3. Other Indications 5.3.1. Syngeneic Model 5.3.2. Patient-Derived Xenograft (PDX) 5.3.3. Xenograft 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. North America 6.2. Latin America 6.3. Europe 6.4. Asia Pacific 6.5. Middle East & Africa (MEA) 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Key Countries Market Analysis 13. Market Structure Analysis 14. Competition Analysis 14.1. Charles River Laboratory 14.2. ICON Plc 14.3. Covance 14.4. Eurofins Scientific 14.5. Taconic Biosciences 14.6. Crown Bioscience 14.7. Toxikon, Inc. 14.8. WuXi AppTec 14.9. EVOTEC 14.10. The Jackson Laboratory 15. Assumptions & Acronyms Used 16. Research Methodology
Explore Healthcare Insights
View Reports
Oncology-Based In-vivo CRO Market
